GENE ONLINE|News &
Opinion
Blog

2025-12-02|

Study Links KIAA1429 Gene to Colorectal Cancer Progression Through FAM84B mRNA Stabilization

by GOAI
Share To

A recent study published in *Biochemical Genetics* has identified a significant connection between the KIAA1429 gene and colorectal cancer progression. Researchers found that KIAA1429 plays a key role in stabilizing FAM84B mRNA, which contributes to tumor development through the Wnt/β-Catenin signaling pathway. The findings provide new insights into the molecular mechanisms driving colorectal cancer, highlighting the impact of this gene on tumorigenesis.

The study examined how KIAA1429 influences FAM84B mRNA stability and its subsequent effects on cellular processes associated with cancer growth. Researchers observed that increased activity of KIAA1429 correlates with enhanced stabilization of FAM84B mRNA, which promotes activation of the Wnt/β-Catenin signaling pathway—a critical driver in colorectal cancer development. These results suggest that KIAA1429 may play a pivotal role in regulating pathways linked to tumor formation and progression. The research offers valuable information for understanding the genetic factors contributing to colorectal cancer and opens avenues for further investigation into potential therapeutic targets.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
LATEST
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
2025-12-04
2025 Healthcare+ Expo Taiwan
Taipei, Taiwan
Scroll to Top